Can you take Calcium chloride with Doryx MPC?

Calcium chloride has a major potential interaction with Acidosis.

Calcium chloride is acidifying. Therapy with calcium chloride should be administered cautiously in patients with or predisposed to acidosis, including those with renal disease, cor pulmonale, severe respiratory obstruction, or respiratory failure. Calcium chloride should not be administered as therapy for hypocalcemia in patients with acidosis associated with renal failure. Clinical monitoring of acid/base balance and calcium concentrations is necessary during calcium chloride therapy.

The doxycycline in Doryx MPC has a moderate potential interaction with Biliary Obstruction.

The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.

Calcium chloride has a moderate potential interaction with Dermatitis, Drug-Induced.

Calcium chloride may lead to tissue necrosis and calcinosis cutis in patients with local trauma due to increase in local calcium levels. To reduce the risk of tissue necrosis, administer this drug slowly through a small needle into a large vein. Avoid extravasation or accidental injection into perivascular tissues. If it occurs, stop the infusion immediately and treat the area as needed.

The doxycycline in Doryx MPC has a moderate potential interaction with Esophageal Obstruction.

The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime. Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia. If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.

The doxycycline in Doryx MPC has a moderate potential interaction with Liver Disease.

The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.

The doxycycline in Doryx MPC has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

Calcium chloride has a major potential interaction with Pulmonary Impairment.

Calcium chloride is acidifying. Therapy with calcium chloride should be administered cautiously in patients with or predisposed to acidosis, including those with renal disease, cor pulmonale, severe respiratory obstruction, or respiratory failure. Calcium chloride should not be administered as therapy for hypocalcemia in patients with acidosis associated with renal failure. Clinical monitoring of acid/base balance and calcium concentrations is necessary during calcium chloride therapy.

Calcium chloride has a major potential interaction with Renal Dysfunction.

Calcium chloride is acidifying. Therapy with calcium chloride should be administered cautiously in patients with or predisposed to acidosis, including those with renal disease, cor pulmonale, severe respiratory obstruction, or respiratory failure. Calcium chloride should not be administered as therapy for hypocalcemia in patients with acidosis associated with renal failure. Clinical monitoring of acid/base balance and calcium concentrations is necessary during calcium chloride therapy.

Calcium chloride has a moderate potential interaction with Renal Dysfunction.

Calcium chloride injection in patients with renal dysfunction may increase the risk of calcium-phosphorus product. Patients with renal dysfunction are at higher risk of aluminum toxicity. In these patients, it is recommended to begin with the lowest dose within the approved range. Serum calcium levels should be monitored frequently, based on the severity of renal dysfunction and the risk of a high calcium-phosphorus product.

Calcium chloride has a major potential interaction with Ventricular Arrhythmia.

Calcium chloride injection is contraindicated in patients with ventricular fibrillation, asystole and electromechanical dissociation.